SAB Biotherapeutics, Inc. (SABS) income statement
SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.81−0.10 (-3.44%)
Close on Nov 20, 2026Market cap $255.67MP/E –Yield –
SAB Biotherapeutics, Inc. financial ratios
See a number that looks wrong?